Table 2.
Visual acuity (VA) and Central subfield macular thickness (CST) at the initial and final follow-up
Oral anti-diabetic agents group (N=46) | Insulin therapy group (N=49) | p | ||
---|---|---|---|---|
VA | Initial | 20/61 ± 20/39 | 20/76 ± 20/55 | 0.239 |
Final | 20/49 ± 20/36 | 20/56 ± 20/60 | 0.489 | |
CST (μm) | Initial | 454.7 ± 142.8 | 471.5 ± 145.3 | 0.586 |
Final | 354.9 ± 120.3 | 368.4 ± 122.9 | 0.591 |